The U.S. vasopressin market is estimated to be valued at US$ 894.6 Mn in 2021, and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).
Figure 1: U.S. Vasopressin Market Share (%) Analysis, By Type, 2021
Increasing regulatory approvals of vasopressin is the major factor that is expected to drive growth of the U.S. vasopressin market over the forecast period.
Increasing regulatory approvals of vasopressin in the U.S. is expected to be the major factor driving the growth of U.S. vasopressin market over the forecast period. For instance, in December 2021, Eagle Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration approved the company’s abbreviated new drug application ‘ANDA’ for vasopressin.
U.S. Vasopressin Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients